GLP-1/GIP is a dual-action treatment that works as both a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, helping to control blood sugar and support weight loss
Clinical studies show that over the span of 72 weeks, patients on tirzepatide lost, on average, 15 to 20 percent of their body weight
doi: 10.1038/ni.3233 71 DavisonJMLickwarCRSongLBretonGCrawfordGERawlsJF
Available in multiple strengths 5MG, 10MG, 15MG, 20MG, and 30MG Semaglutide offers flexible dosing options for different treatment protocols and research needs
Enhanced Mobility and Reduced Fall Risk The weight loss associated with GLP-1 medications can lead to better mobility, improved balance, and a reduced risk of fallsa critical benefit for older adults
Practical tips: Start at the lowest recommended dose and increase as advised